Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2
Barr, Paul M. (University of Rochester)
Robak, Tadeusz (Medical University of Lodz)
Owen, Carolyn (Tom Baker Cancer Centre)
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda)
Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University)
Bartlett, Nancy L. (Washington University School of Medicine)
Burger, Jan A. (University of Texas MD Anderson Cancer Center)
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology)
Coutre, Steven E (Stanford University School of Medicine)
Devereux, Stephen (Kings College Hospital)
Grosicki, Sebastian (School of Public Health. Silesian Medical University)
McCarthy, Helen (Royal Bournemouth Hospital)
Li, Jianyong (Jiangsu Province Hospital)
Simpson, David (North Shore Hospital)
Offner, Fritz (Universitair Ziekenhuis Gent)
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau)
Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company)
Styles, Lori (Pharmacyclics. LLC an AbbVie Company)
James, Danelle (Pharmacyclics. LLC an AbbVie Company)
Kipps, Thomas J (University of California,San Diego. Moores Cancer Center)
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. A total of 269 patients aged ≥65 years with previously untreated chronic lymphocytic leukemia without del(17p) were randomized 1:1 to ibrutinib (n=136) or chlorambucil (n=133) on days 1 and 15 of a 28-day cycle for 12 cycles. Median ibrutinib treatment duration was 28. 5 months. Ibrutinib significantly prolonged progression-free survival versus chlorambucil (median, not reached vs. 15 months; hazard ratio, 0. 12; 95% confidence interval, 0. 07-0. 20; P<0. 0001). The 24-month progression-free survival was 89% with ibrutinib (97% and 89% in patients with del[11q] and unmutated immunoglobulin heavy chain variable region gene, respectively). Progression-free survival rates at 24 months were also similar regardless of age (<75 years [88%], ≥75 years [89%]). Overall response rate was 92% (125/136). Rate of complete response increased substantially from 7% at 12 months to 18% with extended follow up. Greater quality of life improvements occurred with ibrutinib versus chlorambucil in Functional Assessment of Chronic Illness Therapy-Fatigue (P=0. 0013). The most frequent grade ≥3 adverse events were neutropenia (12%), anemia (7%), and hypertension (5%). Rate of discontinuations due to adverse events was 12%. Results demonstrated that first-line ibrutinib for elderly patients with chronic lymphocytic leukemia provides sustained response and progression-free survival benefits over chemotherapy, with depth of response improving over time without new toxicity concerns. This trial was registered at clinicaltrials. gov identifier 01722487 and 01724346.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510, ISSN 1592-8721

DOI: 10.3324/haematol.2018.192328
PMID: 29880603

9 p, 996.2 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats